ImmunityBio Quarterly Balance Sheet
NASDAQ: IBRXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
ImmunityBio financial position
As of Jun 30, 2026, ImmunityBio reported total assets of $628.5 million, up 56.3% from a year earlier against total liabilities of $1.67 billion. Shareholders' equity was negative at -$1.05 billion, meaning liabilities exceed assets; this is often the result of large share buybacks or accumulated losses. The company held $75.7 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 5.72, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
ImmunityBio balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 75.67M | 205.19M | 88.33M | 60.24M | 137.66M | 60.66M | 143.43M | 111.97M | 130.10M | 133.03M | 265.45M | 177.96M |
| Short-Term Investments | 281.70M | 175.69M | 154.48M | 197.57M | 16.00M | 931.00K | 6.38M | 18.40M | 87.88M | 37.46M | 1.01M | 11.83M |
| Receivables | 53.47M | 43.27M | 42.57M | 32.02M | 22.13M | 17.03M | 2.36M | 4.17M | 1.03M | — | 0 | — |
| Inventory | 1.94M | 547.00K | 910.00K | 6.70M | 6.64M | 8.44M | 8.27M | 1.96M | 1.81M | — | 0 | — |
| Total Current Assets | 438.98M | 452.95M | 314.88M | 329.50M | 208.13M | 109.16M | 184.59M | 163.15M | 242.83M | 195.72M | 294.08M | 215.08M |
| Property, Plant & Equipment | 114.22M | 112.78M | 114.26M | 129.60M | 133.00M | 135.27M | 137.09M | 139.28M | 141.96M | 143.52M | 146.08M | 152.00M |
| Goodwill | — | 910.00K | 910.00K | 910.00K | 910.00K | 910.00K | 910.00K | 910.00K | — | — | — | — |
| Intangible Assets | — | 11.91M | 12.99M | 13.53M | 13.51M | 14.02M | 14.53M | 15.04M | 16.06M | 16.57M | 17.09M | 18.47M |
| Long-Term Investments | — | — | — | — | — | — | 0 | 0 | 0 | 0 | 891.00K | 817.00K |
| Total Assets | 628.50M | 646.64M | 501.90M | 518.99M | 402.08M | 303.76M | 382.93M | 364.57M | 444.32M | 400.68M | 504.45M | 432.42M |
| Short-Term Debt | — | 884.00K | 1.75M | 2.60M | — | — | 1.25M | — | — | — | — | — |
| Total Current Liabilities | 76.73M | 67.95M | 61.75M | 57.13M | 50.64M | 49.20M | 54.94M | 60.96M | 62.11M | 53.76M | 58.28M | 90.32M |
| Total Liabilities | 1.67B | 1.52B | 1.00B | 1.04B | 971.89M | 894.24M | 871.06M | 1.11B | 1.14B | 1.09B | 1.09B | 843.06M |
| Shareholders' Equity | -1.05B | -870.01M | -500.47M | -524.32M | -570.75M | -591.43M | -489.10M | -745.15M | -698.39M | -692.01M | -586.99M | -411.72M |
| Retained Earnings | -4.59B | -4.36B | -3.73B | -3.66B | -3.60B | -3.50B | -3.38B | -3.32B | -3.23B | -3.10B | -2.96B | -2.73B |
| Total Debt | — | 884.00K | 1.75M | 2.60M | — | — | 1.25M | — | — | — | — | — |
| Net Cash (Debt) | 357.37M | 380.00M | 241.07M | 255.21M | 153.66M | 61.59M | 148.56M | 130.37M | 217.98M | 170.50M | 266.46M | 189.80M |
| Shares Outstanding | 1.05B | 1.05B | 1.01B | 984.97M | 915.63M | 853.56M | 852.90M | 696.83M | 691.79M | 677.00M | 670.87M | 667.70M |
This table shows 12 quarterly periods of ImmunityBio's balance sheet, from Q2 2026 back to Q3 2023, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow IBRX's reporting calendar. What is a balance sheet?